Twenty years outcomes in a single center experience after endovascular aneurysm repair with unibody endograft and anatomical fixation.
To assess the long-term safety and effectiveness of EVAR treatment with unibody endograft deployed on aortic bifurcation (anatomical fixation). A retrospective, observational, single-center study of patients treated from 1999 to 2002 with unibody bifurcated endograft. Follow-up protocol required clinical and doppler-ultrasound at 1 and 6 months and annually thereafter, computed tomography angiography at 1-, 6- and 12-months and then every year. Primary endpoints included technical and treatment success, survival and freedom from late EVAR failure; secondary endpoints were freedom from late open conversion (LOC), freedom from late re- interventions and endoleaks. 73 patients, mean age of 73 ± 6 years were enrolled. Median follow-up was 6 ± 0.5 years. Technical success was 98.6% (n=71/73; causes of failure: 1 open conversion and 1 type Ib endoleak). A treatment success of 96% (n=69/72) was recorded due to endoleaks (n=2; 1 type Ia and 1 type Ib) and limb occlusion (n=1). Survival at 1, 5, 10, 15 and 18 years was 90%, 58%, 40%, 32% and 23% respectively. One aneurysm-related death for infection of the endograft was registered. EVAR failure was 14 % (n=10/71). Three LOC were recorded and freedom from reinterventions at 1, 5, 10 and 18 years was 99%, 91%, 86% and 86%. Fourteen endoleaks were recorded: Ia (n=6; 42.8%), Ia+Ib (n=1; 7.1%), Ib (n=2; 14.2%) and II (n=5; 35.6%). Four endoleaks were observed, 9 endovascular correction and 1 LOC were required. Endoleaks free survival of 90% at 1-year and 75% at the end of the study. Aneurysm sac shrinkage was observed in 79% (n=56/71). This small, retrospective cohort of anatomically fixed EVAR demonstrated long-term safety and effectiveness. The design of the unibody graft did not substantially change and newer generation should guarantee the same performance.